AU2018259089B2 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production - Google Patents

Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production Download PDF

Info

Publication number
AU2018259089B2
AU2018259089B2 AU2018259089A AU2018259089A AU2018259089B2 AU 2018259089 B2 AU2018259089 B2 AU 2018259089B2 AU 2018259089 A AU2018259089 A AU 2018259089A AU 2018259089 A AU2018259089 A AU 2018259089A AU 2018259089 B2 AU2018259089 B2 AU 2018259089B2
Authority
AU
Australia
Prior art keywords
polymorph
crystalline
cancer
gdc
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018259089A
Other languages
English (en)
Other versions
AU2018259089A1 (en
AU2018259089A9 (en
Inventor
Paroma CHAKRAVARTY
Chong Han
Sean M. Kelly
Karthik Nagapudi
Scott Savage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2018259089A1 publication Critical patent/AU2018259089A1/en
Publication of AU2018259089A9 publication Critical patent/AU2018259089A9/en
Application granted granted Critical
Publication of AU2018259089B2 publication Critical patent/AU2018259089B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2018259089A 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production Active AU2018259089B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
US62/491,812 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (3)

Publication Number Publication Date
AU2018259089A1 AU2018259089A1 (en) 2019-07-04
AU2018259089A9 AU2018259089A9 (en) 2019-10-10
AU2018259089B2 true AU2018259089B2 (en) 2022-05-12

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018259089A Active AU2018259089B2 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production

Country Status (13)

Country Link
US (4) US20180339997A1 (enExample)
EP (2) EP3615541B1 (enExample)
JP (2) JP6998969B2 (enExample)
KR (1) KR102342776B1 (enExample)
CN (1) CN110650963B (enExample)
AU (1) AU2018259089B2 (enExample)
CA (1) CA3048591A1 (enExample)
ES (1) ES3027566T3 (enExample)
IL (3) IL298518B2 (enExample)
MX (1) MX394540B (enExample)
PL (1) PL3615541T3 (enExample)
TW (1) TWI826373B (enExample)
WO (1) WO2018197653A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211775A1 (es) 2015-07-02 2021-09-08 Hoffmann La Roche Compuestos de benzoxacepina oxazolidinona y metodos de uso
ES2953833T3 (es) 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
MX394540B (es) 2017-04-28 2025-03-21 Hoffmann La Roche Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
MX2022000279A (es) * 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
KR20220119610A (ko) * 2019-11-25 2022-08-30 상하이 한서 바이오메디컬 컴퍼니 리미티드 3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170015678A1 (en) * 2015-07-02 2017-01-19 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
ES2444779T3 (es) * 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
MX356804B (es) 2013-12-16 2018-06-13 Hoffmann La Roche Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.
ES2953833T3 (es) * 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
MX394540B (es) 2017-04-28 2025-03-21 Hoffmann La Roche Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170015678A1 (en) * 2015-07-02 2017-01-19 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use

Also Published As

Publication number Publication date
US12410189B2 (en) 2025-09-09
CN110650963A (zh) 2020-01-03
IL298518B2 (en) 2025-05-01
US20230167128A1 (en) 2023-06-01
JP6998969B2 (ja) 2022-02-10
WO2018197653A1 (en) 2018-11-01
US11028100B2 (en) 2021-06-08
AU2018259089A1 (en) 2019-07-04
KR102342776B1 (ko) 2021-12-23
AU2018259089A9 (en) 2019-10-10
CA3048591A1 (en) 2018-11-01
IL298518B1 (en) 2025-01-01
EP4534148A3 (en) 2025-05-21
IL267464A (en) 2019-08-29
BR112019013292A2 (pt) 2019-12-10
JP2021181446A (ja) 2021-11-25
WO2018197653A9 (en) 2019-09-19
US11591345B2 (en) 2023-02-28
JP2020517713A (ja) 2020-06-18
PL3615541T3 (pl) 2025-06-23
US20180339997A1 (en) 2018-11-29
ES3027566T3 (en) 2025-06-16
IL267464B2 (en) 2023-05-01
IL267464B1 (en) 2023-01-01
EP3615541B1 (en) 2025-03-19
CN110650963B (zh) 2022-09-27
EP4534148A2 (en) 2025-04-09
KR20190133724A (ko) 2019-12-03
IL298518A (en) 2023-01-01
IL317762A (en) 2025-02-01
EP3615541A1 (en) 2020-03-04
TW201843160A (zh) 2018-12-16
US20210094970A1 (en) 2021-04-01
MX2019012507A (es) 2019-12-19
US20200399286A1 (en) 2020-12-24
MX394540B (es) 2025-03-21
TWI826373B (zh) 2023-12-21
EP3615541C0 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
US10723730B2 (en) Solid forms of a selective CDK4/6 inhibitor
AU2018372180B2 (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
BR112019013292B1 (pt) Polimorfos anidratos cristalinos, polimorfo triidrato cristalino, composições farmacêuticas, processo para preparar um polimorfo cristalino e uso de um polimorfo cristalino
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof
HK1223101B (zh) Gdc-0032的多晶型物、其制备方法和药物用途
HK1223101A1 (zh) Gdc-0032的多晶型物、其制备方法和药物用途

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ITOVEBI INAVOLISIB

Filing date: 20250326

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ITOVEBI INAVOLISIB

Filing date: 20250326